moxifloxacin has been researched along with triclosan in 5 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (triclosan) | Trials (triclosan) | Recent Studies (post-2010) (triclosan) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 3,373 | 379 | 1,772 |
| Protein | Taxonomy | moxifloxacin (IC50) | triclosan (IC50) |
|---|---|---|---|
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | 0.585 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] FabI | Escherichia coli K-12 | 0.4995 | |
| Carbonyl reductase [NADPH] 1 | Homo sapiens (human) | 0.4 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] FabI | Haemophilus influenzae Rd KW20 | 0.19 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] FabI | Bacillus subtilis subsp. subtilis str. 168 | 0.5 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Mycobacterium tuberculosis H37Rv | 2.8712 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Francisella tularensis subsp. tularensis SCHU S4 | 1.9125 | |
| Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI | Staphylococcus aureus subsp. aureus MRSA252 | 0.4976 | |
| Enoyl-acyl carrier reductase | Toxoplasma gondii | 0.0167 | |
| Enoyl-acyl-carrier protein reductase | Plasmodium falciparum (malaria parasite P. falciparum) | 0.0872 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ambady, A; Bandodkar, B; Bhat, J; Davies, G; Hameed, S; Hegde, N; Holdgate, G; Kumar, A; Madhavapeddi, P; McMiken, H; Murugan, K; Naik, M; Nandishaiah, R; Panda, M; Read, JA; Sambandamurthy, VK; Shinde, V; Shirude, PS; Venkatraman, J | 1 |
| Achar, V; Ambady, A; Awasthy, D; Bandodkar, B; Bellale, E; Chatterji, M; Guptha, S; Kaur, P; McLaughlin, R; Morayya, S; Naik, M; Narayan, A; Panda, M; Raichurkar, A; Ramachandran, V; Ravishankar, S; Sharma, S; V B, V; Vachaspati, P; Whiteaker, J | 1 |
| Balakrishnan, G; Bhat, J; Chatterji, M; Dinesh, N; Ghorpade, S; Gorai, G; Guptha, S; Humnabadkar, V; Iyer, PS; Jena, LK; Kaur, P; Khadtare, P; Naik, M; Nandishaiah, R; Narayan, A; Naviri, LK; Panda, M; Ramachandran, V; Sharma, S | 1 |
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
5 other study(ies) available for moxifloxacin and triclosan
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis.
Topics: Bacterial Proteins; Crystallography, X-Ray; Dose-Response Relationship, Drug; Enzyme Inhibitors; Models, Molecular; Molecular Structure; Mycobacterium tuberculosis; Oxidoreductases; Structure-Activity Relationship; Thiazoles | 2013 |
Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; High-Throughput Screening Assays; Humans; Mice; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Polymorphism, Single Nucleotide; Protein Kinases; Small Molecule Libraries; Structure-Activity Relationship; Thiazoles | 2014 |
2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis.
Topics: | 2014 |
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |